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Drugs of Abuse: Psychedelics and Mental Health

The psychedelic drug class includes mescaline, psilocybin, dimethyltryptamine (DMT),
and D-lysergic acid diethylamide (LSD). Psychedelics have been known to have
‘mind-manifesting’ or ‘soul-revealing’ effects. It is likely that these drugs have been used in
prehistoric times, particularly for church ceremonies, healing practices, and spiritual ceremonies.
By the end of the 1960s, the use of psychedelics shifted and it was being used in medical trials to
see if it could help those with non-psychotic and psychotic mental health issues. Trials including
patients with depression, anxiety, obsessive, and addictive disorders showed promise for
psychedelics having therapeutic potential and a low risk of toxicity. However, research came to a
halt when psychedelics were classified as Schedule I drugs. This schedule means that it has no
accepted medical use and the maximum potential for harm and dependence1. Although this may
be changing soon since scientists are researching the use of psychedelics to treat various mental
health illnesses2.
According to Thomas Anderson, et al. (1970)3, microdosing psychedelics in comparison
to full-dose therapies are showing positive effects on those with depression and anxiety.
Microdosing refers to the practice of consuming very low doses of psychedelic substances such
as LSD or psilocybin rather than taking a full dose of these drugs. While full-dose therapies may
lead to perception-distorting properties, microdosing therapies can lead to clinical benefits. In
this observational study, the control group did not partake in microdosing and were found to

have fewer changes in dysfunctional attitudes, negative emotionality, wisdom, open-mindedness,
and creativity. Those participants that did partake in microdosing were found to have lower
scores on dysfunctional attitudes and negative emotionality and higher on open-mindedness and
creativity. Negative emotionality includes feelings of anxiety, depression, or emotional volatility.
These negative emotions are a predictor of mental and physical health problems3. This displays a
significant difference between those who microdose psychedelics and the non-microdosing
control group.
In another study conducted at John Hopkins University, 51 cancer patients underwent a
randomized, double-blind, crossover trial to investigate the differences in high dose psilocybin
versus low dose psilocybin. Over five weeks, patients were administered a very low, placebo-like
dose of psilocybin (1 or 3 mg) or a high dose of psilocybin (22 or 30 mg). After five weeks and a
six-month follow-up, those who received a high dose of psilocybin showed better outcomes in
anxiety and depression than those who received the placebo. The study also measured death
acceptance, to which those on the high dose psilocybin scored higher as well. As shown in this
study, it is evident that the psilocybin dose helped with anxiety and depression in cancer patients
with a life-threatening diagnosis4.
A similar study conducted at New York University used niacin as the control rather than
the low-dose psilocybin. In this randomized double-blind control trial, 29 patients with
cancer-related anxiety and depression were either placed on niacin or single-dose psilocybin in a
span of seven weeks. Upon the six and a half-week mark, those that received the psilocybin in
this study experienced a decrease in their anxiety and depression, an increased quality of life, and

an improved mood towards death. As in the previous studies, this study displays that the use of
psilocybin under the supervision of professionals can reduce anxiety and depression5.
According to Peter Gasser, et. al, (2014)6 LSD-assisted psychotherapy has positive and
stable outcomes on those with anxiety relating to life-threatening illnesses. 12 patients with
anxiety associated with a life-threatening illness were a part of this double-blind, randomized,
active placebo-control study. The patients either received 200 μg of LSD (freebase) or 20 μg of
LSD (a low dose comparator). After a two-month follow-up, it was found that the patients that
received the 200 μg of LSD had a significant decrease in anxiety. This reduction was sustained
for 12 months. Thus, it was shown that with medically supervised doses of LSD it is possible to
reduce anxiety6.
In 1960, two psychologists at Harvard, Timothy Leary and Richard Alpert, started The
Harvard Psilocybin Project. This project aimed to show the difference between the human mind
while on psychedelics. However, in 1963, Harvard fired Leary and Alpert and shut down their
research project because they were administering LSD to their students2,7. Fortunately, this
outcome is no longer the case for researchers today. As stated previously, scientists are now
exploring the roles of hallucinogens on treatment-resistant depression, post-traumatic stress
disorder, cancer-related anxiety, addictions, and perhaps even anorexia2. While this paper only
includes depression and anxiety, both cancer and non-cancer related, it is evident that
psychedelics have the chance to be a revolutionary drug in pharmacy and medicine alike.
Although studies have begun to show promise in the use of psychedelics for mental health
illnesses, further studies are warranted in the potential use of these medications.
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